Want to see TSE:SVA full AI Analyst Report?
Top Page
Sernova
(TSX:SVA)
Select Model
Select Model
Rating:49Neutral
Price Target:
C$0.14
▲(26.36% Upside)
Action:Reiterated
Date:09/10/26
The score is held down primarily by weak financial performance—no revenue, ongoing losses and cash burn, and notably negative equity that elevates funding risk. Technicals are comparatively supportive with price above major moving averages and positive momentum, but valuation remains constrained by negative earnings and the absence of a dividend.
Positive Factors
Improving Loss Profile
Improving losses indicate progress in controlling the development cost base, even though Sernova remains unprofitable. If this trend persists, it could extend funding runway and reduce the capital required to advance programs before commercialization, supporting greater strategic flexibility.
Negative Factors
No Commercial Revenue
Sernova has no commercial revenue because its lead programs remain in development and require clinical progress and regulatory approval. This leaves near-term financial performance dependent on advancing uncommercialized therapies rather than recurring product demand or established customer relationships.
Read all positive and negative factors
Positive Factors
Negative Factors
Improving Loss Profile
Improving losses indicate progress in controlling the development cost base, even though Sernova remains unprofitable. If this trend persists, it could extend funding runway and reduce the capital required to advance programs before commercialization, supporting greater strategic flexibility.
Read all positive factors
Sernova (SVA) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$52.87M
Dividend YieldN/A
Average Volume (3M)135.29K
Price to Earnings (P/E)―
Beta (1Y)-0.11
Revenue GrowthN/A
EPS Growth48.06%
CountryCA
Employees8
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.04
Shares Outstanding377,642,520
10 Day Avg. Volume217,514
30 Day Avg. Volume135,286
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)-1.96
Price to Sales (P/S)0.00
P/FCF Ratio-4.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$1.00Price Target Upside809.09% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.03
Revenue Forecast (FY)N/A
Sernova Business Overview & Revenue Model
Company Description
Sernova Corp. is a Canadian clinical-stage enterprise specializing in the development and commercialization of groundbreaking regenerative medicine therapies. Its core endeavors revolve around its proprietary Cell Pouch system and associated techn...
How the Company Makes Money
As a clinical-stage biotechnology company, Sernova has historically not had recurring product sales because its lead programs are in development and subject to clinical trial progress and regulatory approval. Accordingly, material, product-based o...
Sernova Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
12
Very Negative
Cash Flow
18
Very Negative
| Breakdown | TTM | Oct 2025 | Oct 2024 | Oct 2023 | Oct 2022 | Oct 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -256.13K | -342.59K | -540.28K | -445.55K | -440.00K | -267.20K |
| EBITDA | -10.22M | -14.74M | -31.25M | -40.19M | -24.54M | -6.60M |
| Net Income | -11.83M | -15.74M | -32.19M | -39.00M | -24.54M | -7.02M |
Balance Sheet | ||||||
| Total Assets | 1.53M | 764.23K | 7.53M | 22.11M | 52.48M | 29.82M |
| Cash, Cash Equivalents and Short-Term Investments | 1.05M | 265.00K | 6.01M | 19.81M | 49.78M | 27.87M |
| Total Debt | 2.45M | 4.77M | 569.94K | 136.12K | 275.98K | 393.35K |
| Total Liabilities | 11.17M | 25.84M | 20.48M | 9.59M | 4.88M | 1.75M |
| Stockholders Equity | -9.64M | -25.08M | -12.96M | 12.51M | 47.61M | 28.07M |
Cash Flow | ||||||
| Free Cash Flow | -5.50M | -10.91M | -18.90M | -30.44M | -14.75M | -6.86M |
| Operating Cash Flow | -5.50M | -10.91M | -18.90M | -30.34M | -14.42M | -6.84M |
| Investing Cash Flow | 24.96K | 24.96K | 11.12M | 34.78M | -46.34M | -228.78K |
| Financing Cash Flow | 4.53M | 5.14M | 5.07M | 503.46K | 36.66M | 31.00M |
Sernova Technical Analysis
Positive
0.11
Price Trends
0.12
Positive
0.14
Positive
0.14
Negative
Market Momentum
<0.01
Negative
67.43
Neutral
80.00
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:SVA, the sentiment is Positive. The current price of 0.11 is below the 20-day moving average (MA) of 0.12, below the 50-day MA of 0.12, and below the 200-day MA of 0.14, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 67.43 is Neutral, neither overbought nor oversold. The STOCH value of 80.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:SVA.
Sernova Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | C$91.14M | 20.98 | 15.04% | 6.94% | 4.11% | 88.39% | |
54 Neutral | C$39.72M | -8.78 | -18.83% | ― | -27.13% | -1752.63% | |
54 Neutral | C$50.54M | -5.83 | -334.08% | ― | ― | 19.02% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | C$52.87M | -4.59 | 57.10% | ― | ― | 48.06% | |
47 Neutral | C$49.12M | -15.91 | 12.68% | ― | 45.72% | 35.82% | |
42 Neutral | C$37.14M | -4.30 | -1661.38% | ― | ― | -40.15% |
* Healthcare Sector Average
TSE:SVA
Sernova
0.14
-0.04
-25.00%
TSE:COV
Covalon Technologies
3.30
1.27
62.56%
TSE:MBX
Microbix Biosystms
0.31
0.07
29.17%
TSE:MIR
Medmira
0.07
-0.02
-20.00%
TSE:NRX
NurExone Biologic
0.65
-0.42
-39.25%
TSE:DTC
Defence Therapeutics
0.48
-0.25
-34.25%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.